All In Biotech

Drug Trial Radar · NCT01223378

Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension

A Randomized, Multicenter, Single-Masked, Parallel-Group Dose Finding Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Open Angle Glaucoma or Ocular Hypertension

Last checked: Nov 20, 2026Latest source record: Jul 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 413 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

413

Actual

Start

Dec 13, 2010

Primary completion

Dec 20, 2011

Study completion Jun 22, 2012

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Oct 19, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Screening
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this clinical investigation is to determine the most effective drug concentration(s) of BOL-303259-X in the reduction of IOP in order to support further clinical development of an appropriate dose with regard to efficacy, and ocular and systemic safety.

Conditions

  • Intraocular Pressure

Interventions

  • BOL-303259-XDrug

    ophthalmic solution, various concentrations, once daily (QD) 28 days

  • LatanoprostDrug

    0.005% ophthalmic solution, QD 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Mean Diurnal IOP at Visit 6 (Day 28)Time frame: Baseline and Visit 6 (Day 28)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bausch & Lomb, Inc

    Rochester, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.